[1]
1Department of Pharmacoepidemiology, Strathclyde Institute of Pharmacy and Biomedical
Sciences, University of Strathclyde
Glasgow, United Kingdom
[2]
2Pharmaceutical Department, National Association of Statutory Health Insurance Funds
Berlin, Germany
[3]
3Health Economics Centre, University of Liverpool Management School
Liverpool, United Kingdom
[4]
4Division of Clinical Pharmacology, Karolinska Institutet
Stockholm, Sweden
[5]
5Department of Health
Ecorys, Rotterdam, Netherlands
[6]
6National Research Institution for Public Health
Moscow, Russia
[7]
7Mechanism of Coordinated Access to Orphan Medicinal Products (MoCA)
Brussels, Belgium
[8]
8Department of Pharmaceutical Policy, National Institute for Health and Disability
Insurance
Bruxelles, Belgium
[9]
9Zilveren Kruis Achmea
Leiden, Netherlands
[10]
10Department of Drug Management, Faculty of Health Sciences, Jagiellonian University
Medical College
Kraków, Poland
[11]
11Clinical Pharmacology Service, University Hospital Vall d'Hebron, Universitat Autonoma
de Barcelona
Barcelona, Spain
[12]
12Department of Healthcare Development, Stockholm County Council
Stockholm, Sweden
[13]
13Department of Medicine Solna, Karolinska Institutet
Stockholm, Sweden
[14]
14Medicinal Products Department, Health Insurance Institute of Slovenia
Ljubljana, Slovenia
[15]
15Global Health and Development Group, Imperial College
London, United Kingdom
[16]
16Department of Pharmacy, Ministry of Health of the Republic of Lithuania
Vilnius, Lithuania
[17]
17National Health Care Institute (ZIN)
Diemen, Netherlands
[18]
18Department of Pathology, Forensic Medicine and Pharmacology, Faculty of Medicine,
Vilnius University
Vilnius, Lithuania
[19]
19State Medicines Control Agency
Vilnius, Lithuania
[20]
20Scottish Medicines Consortium
Glasgow, United Kingdom
[21]
21Clinical Research and Drug Assessment Unit
Verona, Italy
[22]
22Pediatric Cardiology, Primary Healthcare Centre “Zemun”
Belgrade, Serbia
[23]
23Department of Post-authorisation Safety, State Agency of Medicines
Tartu, Estonia
[24]
24Wissenschaftliches Institut der AOK
Berlin, Germany
[25]
25Faculty of Medicine, Public Health and Management Department, “Carol Davila” University
of Medicine and Pharmacy Bucharest
Bucharest, Romania
[26]
26Ministry of Health and Social Welfare
Banja Luka, Bosnia and Herzegovina
[27]
27Department of Social Pharmacy, Medical Faculty, University of Banja Luka
Banja Luka, Bosnia and Herzegovina
[28]
28Department of Health Services, Ministry of Health
Reykjavík, Iceland
[29]
29Norwegian Directorate for Health
Oslo, Norway
[30]
30Department of Social Pharmacy and Pharmacoeconomics, Faculty of Pharmacy, Medical
University of Sofia
Sofia, Bulgaria
[31]
31Institut de Recherche et Documentation en Economie de la Santé (IRDES)
Paris, France
[32]
32KU Leuven Department of Pharmaceutical and Pharmacological Sciences
Leuven, Belgium
[33]
33Health Technology Assessment, Pricing and Reimbursement Department, Central Administration
of the Health System, National Authority of Medicines and Health Products (I.P., INFARMED)
Lisboa, Portugal
[34]
34Barcelona Health Region, Catalan Health Service
Barcelona, Spain
[35]
35Department of Pharmaceutical Affairs, Main Association of Austrian Social Insurance
Institutions
Vienna, Austria
License:
This is an open-access article distributed under the terms of the Creative Commons
Attribution License (CC BY). The use, distribution or reproduction in other forums
is permitted, provided the original author(s) or licensor are credited and that the
original publication in this journal is cited, in accordance with accepted academic
practice. No use, distribution or reproduction is permitted which does not comply
with these terms.